DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Lacidipine (Drug); Bendrofluazide (Drug); Placebo (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

The aim of this study is to compare the effects of lacidipine on markers of platelet activation and other rheological factors in hypertensive patients with those of bendrofluazide

Clinical Details

Official title: A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Changes in ß-TG (thromboglobulin)

Secondary outcome:

Changes in soluble p-selectin

Changes in rheological factors

Changes in lipid levels between randomisation and last visit

Number of patients with clinical significant findings in laboratory parameters

Number of patients with adverse events

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age 18 or over

- Hypertensive at screening: Diastolic blood pressure (DBP) 95 - 115 mm Hg and / or

systolic blood pressure (SBP) >= 160 mm Hg on no therapy or on monotherapy. If currently on monotherapy, DBP could have been < 95 mm Hg and SBP < 160 mm Hg, but the patient must have been experiencing unacceptable side effects from their current treatment. Patient must then be able to stop treatment for the placebo run in phase of four weeks without endangering their health (at investigator's discretion)

- Hypertensive at randomisation: DBP 95-115 mm Hg and or SBP >=160

- Able to give written informed consent

Exclusion Criteria:

- Grad III or grad IV hypertensive retinopathy

- Renal impairment; serum creatinine > 150 µmol/L

- Heart failure. (New York Heart Association (NYHA) Class III or IV)

- Liver impairment (abnormal Liver function test (LFT) with aspartate-amino transferase

(AST) / alanine-amino transferase (ALT) > 2x upper normal limit or bilirubin > 2x upper normal limit)

- Recent (< 2 months) history of unstable angina

- Recent (< 2 months) history of myocardial infarction

- Recent (< 2 months) history of stroke

- History of diabetes mellitus or impaired glucose tolerance or random blood glucose >=

9 mMol/L

- Any acute systemic illness or infection

- Any severe disease which could interfere with survival or well-being during the study

(e. g. malignancy)

- Patients of child bearing potential

- Current or previous drug and / or alcohol abuse

- Severely limited venous access

- Haemoglobin < 10g/dL (male patients), haemoglobin < 9g/dL (female patients)

- Requirement for anticoagulant therapy

- Severe valvular heart disease (investigator's discretion)

- Atrial fibrillation or other serious cardiac dysrhythmia

- History of thyroid disease or abnormal thyroid function test (thyroid stimulating

hormone (TSH) < 0. 4 mU/L or > 5. 4 mU/L)

- History of connective tissue disorder

- Concurrent participation in any other clinical trial or participation within two

months enrolment

- Requirement for restricted drugs

- Patients currently on treatment with lacidipine or bendrofluazide (BNFZ)

- Patients unable to attend clinics

- Any clinical condition which in the opinion of the investigator, would preclude the

safe fulfillment of the protocol and the safe administration of trial medication

- Seated blood pressure (BP) exceeding either 210 mm Hg (systolic) or 115 mm Hg

(diastolic) at screening or randomization

- Standing BP < 140 mm Hg (systolic) and < 95 mm Hg (diastolic) at randomization

Locations and Contacts

Additional Information

Starting date: December 1997
Last updated: September 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017